Crystalline Drug-Linker Intermediate for Chromatography-Free ADCs
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing methods for producing a drug-linker intermediate for antibody-drug conjugates require complex purification steps like chromatography, which are not industrially efficient.
Innovation Solution
A method to produce the drug-linker intermediate as crystals using specific solvent combinations, such as lower ketones and alcohols, eliminating the need for chromatography and ensuring high purity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Manufacturing precision
If conventional methods are used to produce drug-linker intermediate, then the product can be obtained, but complex purification steps like chromatography are required
Solution Approach 1:
The invention changes the physical state parameter of the product from amorphous to crystalline form. By optimizing crystallization conditions (solvent selection, temperature control, pH adjustment), the drug-linker intermediate forms well-defined crystals that can be purified through simple filtration and washing, eliminating the need for complex chromatography while maintaining high purity
Solution Approach 2:
The invention utilizes the phase transition from dissolved state to crystalline state during product formation. By controlling the crystallization process through solvent selection (e.g., acetone, ethanol, isopropanol) and temperature variations, the product precipitates as pure crystals that can be easily separated from impurities, replacing complex purification steps with simple phase separation
2Manufacturing precision
If conventional methods are used to produce drug-linker intermediate, then the product can be obtained, but time-consuming purification steps are required
Solution Approach 1:
The invention employs controlled crystallization where the drug-linker intermediate transitions from dissolved to solid crystalline phase. This phase transition naturally separates the product from impurities in the mother liquor, allowing rapid filtration and washing that dramatically reduces purification time compared to chromatography while maintaining high purity standards
3Manufacturing precision
If conventional methods are used to produce drug-linker intermediate, then the product can be obtained, but industrial efficiency is reduced
Solution Approach 1:
The invention optimizes multiple parameters simultaneously (solvent type, temperature, pH, concentration) to achieve direct crystallization of high-purity product. This approach enables scalable industrial production where large volumes can be processed through simple crystallization-filtration-washing sequences, dramatically improving productivity while maintaining consistent product quality
Solution Approach 2:
The invention extracts the purification function from complex chromatographic processes and replaces it with selective crystallization. By designing the synthesis pathway to produce crystalline product directly, the impurities remain in the mother liquor and are easily separated, enabling efficient industrial-scale production with minimal purification infrastructure
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The method allows for the production of high-quality drug-linker intermediates as crystals, facilitating the production of antibody-drug conjugates without chromatography, enhancing industrial efficiency.
Implementation Method 1
the compound represented by formula (1) can be obtained as crystals
Implementation Method 2
precipitating crystals of the compound represented by the formula (1) from the solution
Data Source
Figure 1~2
Figure 3~4
Figure 5~6
AI summary
Crystals of the compound represented by formula (1), a method for the production thereof, and a method for producing an antibody-drug conjugate using the crystals.